Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | unknown | — |
Migraine headache; throwing up four times; Case reference number US-BN-2025-001152 is a spontaneous case initially received from a consumer (reference number: EMG2025-451) on 05-Jul-2025 and concerns a female patient with unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, route or site of administration for an unknown indication. On an unspecified date, an unknown amount of time from the first dose, in the morning the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, route or site of administration. On an unspecified date, the patient had a bad migraine headache and started vomiting. The patient thrown up four times over couple hours. On an unspecified date, as corrective treatment for migraine the patient took almotriptan. At the time of initial report, it was unknown if patient recovered from the events of migraine headache and 'vomiting'. The reporter assessed the events of migraine headache and 'vomiting' as non-serious. The reporter causality assessment for the events of migraine headache and 'vomiting'. Additional information received from a consumer via Med Communication (reference number: USBAV25-1620). New information included seriousness assessment, patient information and additional reference number.; Reporter's Comments: This case concerns of a female patient with unspecified age, who experienced non-serious events of migraine and vomiting, on unspecified date, after the patient took the second dose of Vivotif for an unknown indication. Vomiting is listed as per CCDS v8 and expected per SmPC, whilst migraine is unlisted and unexpected. Patient's medical history and concomitant medication details were not provided. Corrective treatment included almotriptan. Outcome is unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the reported events have been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: This case concerns of a female patient with unspecified age, who experienced non-serious events of migraine and vomiting, on unspecified date, after the patient took the second dose of Vivotif for an unknown indication. Vomiting is listed as per CCDS v8 and expected per SmPC, whilst migraine is unlisted and unexpected. Patient's medical history and concomitant medication details were not provided. Corrective treatment included almotriptan. Outcome is unknown. Considering implied temporal relationship and since the contributory role of the suspect vaccine cannot be excluded with certainty, the reported events have been considered as related to Vivotif. This case is considered as non-serious.
Comments: NONE